Cargando…

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model

PURPOSE: The aim of this study was to evaluate changes in body weight, liver weight, blood glucose, liver injury markers, pro-inflammatory factors and oxidative stress marker levels in obese mice with HFD induced NAFLD after semaglutide use. PATIENTS AND METHODS: The 24 C57BL6J mice were randomly di...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Shu, Chen, Shuchun, Chen, Xing, Ren, Qingjuan, Yue, Lin, Pan, Xiaoyu, Zhao, Huiying, Li, Zelin, Chen, Xiaoyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780435/
https://www.ncbi.nlm.nih.gov/pubmed/36568109
http://dx.doi.org/10.3389/fendo.2022.1046130
_version_ 1784856837358616576
author Niu, Shu
Chen, Shuchun
Chen, Xing
Ren, Qingjuan
Yue, Lin
Pan, Xiaoyu
Zhao, Huiying
Li, Zelin
Chen, Xiaoyi
author_facet Niu, Shu
Chen, Shuchun
Chen, Xing
Ren, Qingjuan
Yue, Lin
Pan, Xiaoyu
Zhao, Huiying
Li, Zelin
Chen, Xiaoyi
author_sort Niu, Shu
collection PubMed
description PURPOSE: The aim of this study was to evaluate changes in body weight, liver weight, blood glucose, liver injury markers, pro-inflammatory factors and oxidative stress marker levels in obese mice with HFD induced NAFLD after semaglutide use. PATIENTS AND METHODS: The 24 C57BL6J mice were randomly divided into three groups (NCD, HFD and Sema) for the assessment of metabolic status, inflammatory factor and oxidative stress marker levels, liver histopathology in mice. Liver metabolomics was determined by liquid chromatography/mass spectrometry (LC-MS) method. RESULTS: The mice body weight, liver weight, blood glucose, TG, TCHO, LDL and pro-inflammatory factors were significantly reduced after semaglutide. Meanwhile, semaglutide increased the SOD level. Semaglutide treatment significantly improved the pathological changes such as hepatocyte steatosis, balloon degeneration and lymphoid foci by HE. It also significantly reduced lipid droplet by Oil Red O. The mitochondria were swollen, the volume increased, the cristae were partially broken and reduced, the intramembrane matrix was partially dissolved, and the mitophagy structure was visible in the visual field. There were 6 metabolites down-regulated and 2 metabolites significantly up-regulated after semaglutide treatment. CONCLUSIONS: Semaglutide can reduce blood glucose level and liver fat accumulation and play an anti-inflammatory role in advanced NAFLD that due to the effects of HFD.
format Online
Article
Text
id pubmed-9780435
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97804352022-12-24 Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model Niu, Shu Chen, Shuchun Chen, Xing Ren, Qingjuan Yue, Lin Pan, Xiaoyu Zhao, Huiying Li, Zelin Chen, Xiaoyi Front Endocrinol (Lausanne) Endocrinology PURPOSE: The aim of this study was to evaluate changes in body weight, liver weight, blood glucose, liver injury markers, pro-inflammatory factors and oxidative stress marker levels in obese mice with HFD induced NAFLD after semaglutide use. PATIENTS AND METHODS: The 24 C57BL6J mice were randomly divided into three groups (NCD, HFD and Sema) for the assessment of metabolic status, inflammatory factor and oxidative stress marker levels, liver histopathology in mice. Liver metabolomics was determined by liquid chromatography/mass spectrometry (LC-MS) method. RESULTS: The mice body weight, liver weight, blood glucose, TG, TCHO, LDL and pro-inflammatory factors were significantly reduced after semaglutide. Meanwhile, semaglutide increased the SOD level. Semaglutide treatment significantly improved the pathological changes such as hepatocyte steatosis, balloon degeneration and lymphoid foci by HE. It also significantly reduced lipid droplet by Oil Red O. The mitochondria were swollen, the volume increased, the cristae were partially broken and reduced, the intramembrane matrix was partially dissolved, and the mitophagy structure was visible in the visual field. There were 6 metabolites down-regulated and 2 metabolites significantly up-regulated after semaglutide treatment. CONCLUSIONS: Semaglutide can reduce blood glucose level and liver fat accumulation and play an anti-inflammatory role in advanced NAFLD that due to the effects of HFD. Frontiers Media S.A. 2022-12-09 /pmc/articles/PMC9780435/ /pubmed/36568109 http://dx.doi.org/10.3389/fendo.2022.1046130 Text en Copyright © 2022 Niu, Chen, Chen, Ren, Yue, Pan, Zhao, Li and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Niu, Shu
Chen, Shuchun
Chen, Xing
Ren, Qingjuan
Yue, Lin
Pan, Xiaoyu
Zhao, Huiying
Li, Zelin
Chen, Xiaoyi
Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
title Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
title_full Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
title_fullStr Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
title_full_unstemmed Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
title_short Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
title_sort semaglutide ameliorates metabolism and hepatic outcomes in an nafld mouse model
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780435/
https://www.ncbi.nlm.nih.gov/pubmed/36568109
http://dx.doi.org/10.3389/fendo.2022.1046130
work_keys_str_mv AT niushu semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT chenshuchun semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT chenxing semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT renqingjuan semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT yuelin semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT panxiaoyu semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT zhaohuiying semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT lizelin semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel
AT chenxiaoyi semaglutideamelioratesmetabolismandhepaticoutcomesinannafldmousemodel